The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors.
Lacouture
Mario E
ME
Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, USA. m-lacouture@northwestern.edu
Basti
Surendra
S
Patel
Jyoti
J
Benson
Al
A
D000465:Algorithms; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000627:therapeutic use; D003880:Dermatology; D004318:Doxycycline / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D005076:Exanthema / Q000139:chemically induced / Q000188:drug therapy; D005128:Eye Diseases / Q000139:chemically induced; D005260:Female; D006801:Humans; D007400:Interprofessional Relations; D008175:Lung Neoplasms / Q000188:drug therapy*; D008495:Medical Oncology; D008875:Middle Aged; D009885:Ophthalmology; D011799:Quinazolines / Q000009:adverse effects*; D012017:Referral and Consultation; D012871:Skin Diseases / Q000139:chemically induced* / Q000188:drug therapy; D016559:Tacrolimus / Q000031:analogs & derivatives / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D003879:Dermatologic Agents; D011799:Quinazolines; C117268:pimecrolimus; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D004318:Doxycycline; D016559:Tacrolimus